Agios Pharmaceuticals (AGIO)

$29.17 +4.58 (18.63%)
Market Cap 1.43B
Revenue (ttm) 36.50M
Net Income (ttm) 673.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 1,845.84%
Debt to Equity Ratio 0.00
Volume 6,310,400
Avg Vol 1,691,268
Day's Range N/A - N/A
Shares Out 58.31M
Stochastic %K 85%
Beta 0.87
Analysts Strong Sell
Price Target $32.12

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatr...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 649 8600
Address:
88 Sidney Street, Cambridge, United States
stu4
stu4 Dec. 25 at 1:08 PM
$AGIO AVOID ..Garbage, led by misfits who took this down 55% YOY . Unqualified senior execs, to build value ! Been selling parts of the company , like auctioneers, to keep the pay checks coming , and producing no value in their Petrie Dishes !
0 · Reply
stu4
stu4 Dec. 25 at 1:03 PM
$AGIO here is his own price , lol 12/10/24 ..can anyone help me to do his math that 1 YEAR LATER , he is up 15% and climbing ??? “ spring is coiled tight …blah blah, blah “ YOY FACT : NEGATIVE 55% , YOY …let’s do CAT in that time frame , shall we !!! hahahaha 68% increase in the same time frame …OH MY !!!
0 · Reply
stu4
stu4 Dec. 25 at 12:54 PM
$AGIO one has to read this ….last December , lol when written, by whomever the poster he calls out , this pos was at $62 !!! Then the BIG LIE , not the election of 2020, which wasn’t a lie ! But here , they had to announce, ( knowing all along , reading data for multiple years ) we have a liver issue !!! And today , 12 months later , this buffoon @Mindmld wants you to believe , he is up 15%, YOY His math , is similar to that of Trump, cantor Fitz ( LUTNICK ) and new 700% drug price reduction , hahaha Let’s all send him a math tutor for his YOY , 15% increase since 12/16/24 !!! At this whopping price of $28.76 No wonder Atari lost its edge in gaming , Super Mario was that dumb !
0 · Reply
nokej13957
nokej13957 Dec. 25 at 9:13 AM
$AGIO
0 · Reply
CH_Expat
CH_Expat Dec. 25 at 7:47 AM
$AGIO Valuewise a no-brainer now under 30.
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 25 at 4:59 AM
$AGIO Massive volume spike of 7x the average with 6.3M shares traded as price remains at $29.17. Price has been quite volatile with recent lows at $22.34 and highs at $45.49. Smart traders keep an eye on this one and wait for a lower H% before considering an entry.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 25 at 4:17 AM
$AGIO trading at $29.17, quite a jump from the recent low of $24.59 with volumes around 6.3M.
0 · Reply
RuthOster
RuthOster Dec. 25 at 3:45 AM
$CVKD Quiet no more — Cadrenal’s expansion play gains traction in the market: https://finance.yahoo.com/news/cadrenals-quiet-expansion-play-starting-160000079.html $AGIO $QQQ $SPY $XCLL
0 · Reply
StockOrTwist
StockOrTwist Dec. 25 at 3:19 AM
$AGIO https://www.youtube.com/watch?v=_5QiYVQyiOk
0 · Reply
mikesterz7
mikesterz7 Dec. 25 at 2:48 AM
$AGIO AQVESME will be available in the U.S. in late January 2026 after implementation of an FDA REMS requiring liver tests and education.
0 · Reply
Latest News on AGIO
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

Dec 24, 2025, 4:56 PM EST - 15 hours ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

Agios Pharma Stock: A Buy After FDA Approves Aqvesme

Dec 24, 2025, 12:48 PM EST - 19 hours ago

Agios Pharma Stock: A Buy After FDA Approves Aqvesme

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Dec 24, 2025, 9:56 AM EST - 22 hours ago

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

Dec 24, 2025, 8:22 AM EST - 1 day ago

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Dec 23, 2025, 7:45 PM EST - 1 day ago

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Dec 8, 2025, 7:00 AM EST - 17 days ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript

Nov 19, 2025, 2:33 PM EST - 5 weeks ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript

Why Is Agios Pharmaceuticals Stock Sinking Today?

Nov 19, 2025, 12:30 PM EST - 5 weeks ago

Why Is Agios Pharmaceuticals Stock Sinking Today?

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Nov 19, 2025, 8:24 AM EST - 5 weeks ago

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Nov 19, 2025, 7:00 AM EST - 5 weeks ago

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones

Nov 4, 2025, 1:47 AM EST - 7 weeks ago

Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:01 AM EST - 7 weeks ago

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 2:06 PM EDT - 7 weeks ago

Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 6:30 AM EDT - 2 months ago

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Oct 17, 2025, 8:15 AM EDT - 2 months ago

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Oct 17, 2025, 8:00 AM EDT - 2 months ago

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Oct 16, 2025, 7:00 AM EDT - 2 months ago

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Sep 18, 2025, 5:49 AM EDT - 3 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Sep 15, 2025, 12:20 PM EDT - 3 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Sep 8, 2025, 10:32 AM EDT - 3 months ago

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

Sep 4, 2025, 12:46 PM EDT - 3 months ago

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Sep 4, 2025, 10:49 AM EDT - 3 months ago

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Sep 4, 2025, 7:00 AM EDT - 4 months ago

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Aug 4, 2025, 4:01 PM EDT - 5 months ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:02 PM EDT - 5 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 6:30 AM EDT - 5 months ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Jul 14, 2025, 7:00 AM EDT - 5 months ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Agios Appoints Dr. Jay Backstrom to Board of Directors

Jul 8, 2025, 7:00 AM EDT - 6 months ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Jun 9, 2025, 8:40 AM EDT - 7 months ago

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 28, 2025, 7:00 AM EDT - 7 months ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 14, 2025, 10:00 AM EDT - 8 months ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

May 9, 2025, 7:00 AM EDT - 8 months ago

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

May 2, 2025, 7:00 AM EDT - 8 months ago

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 12:06 PM EDT - 8 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 6:30 AM EDT - 8 months ago

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Apr 17, 2025, 7:00 AM EDT - 9 months ago

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Mar 5, 2025, 5:52 PM EST - 10 months ago

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios to Present at Upcoming Investor Conferences

Mar 4, 2025, 7:00 AM EST - 10 months ago

Agios to Present at Upcoming Investor Conferences

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Feb 20, 2025, 7:00 AM EST - 11 months ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 1:32 PM EST - 11 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 13, 2025, 6:31 AM EST - 11 months ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Feb 13, 2025, 6:30 AM EST - 11 months ago

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Feb 6, 2025, 7:00 AM EST - 11 months ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

Jan 8, 2025, 8:00 AM EST - 1 year ago

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BIIB

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Jan 3, 2025, 7:00 AM EST - 1 year ago

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

Dec 18, 2024, 7:00 AM EST - 1 year ago

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Dec 8, 2024, 12:40 PM EST - 1 year ago

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

Nov 5, 2024, 9:05 AM EST - 1 year ago

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

stu4
stu4 Dec. 25 at 1:08 PM
$AGIO AVOID ..Garbage, led by misfits who took this down 55% YOY . Unqualified senior execs, to build value ! Been selling parts of the company , like auctioneers, to keep the pay checks coming , and producing no value in their Petrie Dishes !
0 · Reply
stu4
stu4 Dec. 25 at 1:03 PM
$AGIO here is his own price , lol 12/10/24 ..can anyone help me to do his math that 1 YEAR LATER , he is up 15% and climbing ??? “ spring is coiled tight …blah blah, blah “ YOY FACT : NEGATIVE 55% , YOY …let’s do CAT in that time frame , shall we !!! hahahaha 68% increase in the same time frame …OH MY !!!
0 · Reply
stu4
stu4 Dec. 25 at 12:54 PM
$AGIO one has to read this ….last December , lol when written, by whomever the poster he calls out , this pos was at $62 !!! Then the BIG LIE , not the election of 2020, which wasn’t a lie ! But here , they had to announce, ( knowing all along , reading data for multiple years ) we have a liver issue !!! And today , 12 months later , this buffoon @Mindmld wants you to believe , he is up 15%, YOY His math , is similar to that of Trump, cantor Fitz ( LUTNICK ) and new 700% drug price reduction , hahaha Let’s all send him a math tutor for his YOY , 15% increase since 12/16/24 !!! At this whopping price of $28.76 No wonder Atari lost its edge in gaming , Super Mario was that dumb !
0 · Reply
nokej13957
nokej13957 Dec. 25 at 9:13 AM
$AGIO
0 · Reply
CH_Expat
CH_Expat Dec. 25 at 7:47 AM
$AGIO Valuewise a no-brainer now under 30.
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 25 at 4:59 AM
$AGIO Massive volume spike of 7x the average with 6.3M shares traded as price remains at $29.17. Price has been quite volatile with recent lows at $22.34 and highs at $45.49. Smart traders keep an eye on this one and wait for a lower H% before considering an entry.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 25 at 4:17 AM
$AGIO trading at $29.17, quite a jump from the recent low of $24.59 with volumes around 6.3M.
0 · Reply
RuthOster
RuthOster Dec. 25 at 3:45 AM
$CVKD Quiet no more — Cadrenal’s expansion play gains traction in the market: https://finance.yahoo.com/news/cadrenals-quiet-expansion-play-starting-160000079.html $AGIO $QQQ $SPY $XCLL
0 · Reply
StockOrTwist
StockOrTwist Dec. 25 at 3:19 AM
$AGIO https://www.youtube.com/watch?v=_5QiYVQyiOk
0 · Reply
mikesterz7
mikesterz7 Dec. 25 at 2:48 AM
$AGIO AQVESME will be available in the U.S. in late January 2026 after implementation of an FDA REMS requiring liver tests and education.
0 · Reply
hegdaom
hegdaom Dec. 25 at 2:05 AM
$AGIO this stu guy is a nasty fucking troll, good riddance, turd.
0 · Reply
hegdaom
hegdaom Dec. 25 at 2:00 AM
$AGIO thx FDA for the gifts! $CAPR
0 · Reply
hegdaom
hegdaom Dec. 25 at 1:59 AM
$AGIO
0 · Reply
hegdaom
hegdaom Dec. 25 at 1:58 AM
$AGIO
0 · Reply
CATraders5
CATraders5 Dec. 25 at 1:55 AM
Will fiscal dominance drive the term premium higher and force a potentially fragmented Fed to engage in financial repression? I think the answer is “likely,” unless the Fed can steepen the curve and deregulate the banks enough to have the banks do the work for it. According to $AGIO $OMER $AVNT
0 · Reply
hegdaom
hegdaom Dec. 25 at 1:51 AM
$AGIO
0 · Reply
hegdaom
hegdaom Dec. 25 at 1:49 AM
$AGIO this gonna wipe out shorts BADLY!!
0 · Reply
hegdaom
hegdaom Dec. 25 at 1:49 AM
$AGIO thx @ripztrip for recommending!!!
0 · Reply
Holdyn_Baggins
Holdyn_Baggins Dec. 25 at 1:43 AM
$AGIO 👀
1 · Reply
TrendDecoded
TrendDecoded Dec. 25 at 1:39 AM
$ASTS $GD $GIS $AGIO 🚨🚨Are your children about to go to bed peacefully before Christmas? 🚨🚨 Want to spice things up and get them all riled up when they should be sleeping? Read on... $ASTS
0 · Reply
stu4
stu4 Dec. 25 at 1:25 AM
$AGIO Wrong Highest $62.10 …lowest $16.95 Absolute, LOSERS AT THE HELM
0 · Reply
stu4
stu4 Dec. 25 at 1:23 AM
$AGIO ..your Chairwoman..so busy on your behalf, creating value in Agios, by Surrounding herself with investors , deep pockets ! Afterall, she only took your value from $48 on her arrival in 12/2018 ..to $ 28 ..7 years of NOTHING NEGATIVE 50% ROI WHEREAS AT ALNY , Yvonne Greenstreet took her biotech up a Double from $200 in 4 short years .$ALNY … Guess you can be so happy with your investment !!! Look up Jackie Fouse in Webster’s Dictionary….you will see a picture of her next to : Loser
0 · Reply